![](https://thehcdata.com/wp-content/uploads/2023/05/pexels-tima-miroshnichenko-8376291.webp)
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the promotion of Michael Sherman Blue, M.D., FACEP to the position of Chief Medical Officer (CMO), reporting directly to the Company’s Board of Directors. Dr. Blue’s appointment aligns with the Company’s stated objectives and its Fix, Fund, Propel approach to advancing innovative technology to market.
“I am honored to step into the role of Chief Medical Officer, and ready to get to work so we can place our innovative solutions in the hands of those who need them most.”
Demonstrated Leadership, Clinical Expertise, Business Acumen
Michael Blue, M.D., FACEP’s appointment to the role of CMO, expanding his previous role as Senior Medical Director, continues Navidea’s work, supported by G2G Ventures as Executive Consultants, to ensure well-defined organizational roles, clear priorities and strong leadership to guide the Company forward. In his role, Dr. Blue’s responsibilities include product strategy and development, marketing, financial performance, and delivery of shareholder value. Dr. Blue, reporting to the Board of Directors, will oversee the delivery of Navidea’s NAV3-32 and NAV3-33 clinical trials, and the development of expert teams responsible for advancing its innovative technology to market.
“Dr. Blue’s experience in precision immunodiagnostics, immunotherapeutics and the biotech industry is important as we continue pressing the business forward,” said Dr. Jason Myers, Owner and Founder of G2G Ventures. “Since joining the Company over a decade ago, Dr. Blue has certainly gained the support and confidence of his colleagues. His understanding of the business side of innovation and driving our clinical trials, in concert with his perspective and experience working with patients, will help bring Navidea’s technology and assets to the forefront.”
Dr. Blue has served as Senior Medical Director at Navidea since 2011, continuing a decorated career of over 40 years in medicine which has included roles within emergency center care, cardiometabolic care, service within committees and community focused medical advisory positions, leadership roles within hospitals, and educational roles within multiple universities. His experience also includes having led healthcare related research for a regional venture capital firm. Dr. Blue is former Chairman of the Department of Emergency Medicine at St Ann’s Hospital, former member of the Board of Directors for the Central Ohio Trauma System, and is currently Medical Director for Cardinal Health NPHS. Dr. Blue earned a B.S. in Zoology from Miami University, where he was also Miami’s Scholar Athlete of the Year, and a Doctor of Medicine (M.D.) from the Ohio State University School of Medicine. He holds medical licenses in Ohio, California and Florida, along with ACLS Certification. Dr. Blue is a member of the American College of Emergency Physicians and a Fellow of the American Board of Emergency Medicine, where he also holds a Board Certification in Emergency Medicine (FACEP).
Dr. Blue has led or contributed to 16 clinical trials related to Lymphoseek® and concepts related to Navidea’s Manocept platform, and has published extensively in peer reviewed journals throughout his career.
“Navidea’s transformative technology holds the potential to improve lives around the world in many ways,” said Dr. Blue. “I am honored to step into the role of Chief Medical Officer, and ready to get to work so we can place our innovative solutions in the hands of those who need them most.”
Source: https://www.businesswire.com/